teaser
“In the first three months of 2010 more than 116 000 patients benefited from UCB’s new medicines,” said Roch Doliveux, CEO of UCB. “Our new products Cimzia, Vimpat and Neupro are building momentum and laying the foundation for UCB’s future growth. After the first three months we are also delighted to confirm that we are on track to deliver our guidance.”
The new products Cimzia, Vimpat and Neupro showed solid growth with multiple new launches proceeding as planned across various European countries. In addition, the company’s anti-epileptic drug, Keppra (levetiracetam), continued to grow in most European countries, due to continued increase in its use in monotherapy. The growth drivers largely offset the expected revenue decline in the first quarter 2010 compared to the same period in 2009 due to the effect of Keppra U.S. patent expiry and the impact of the divestitures to GlaxoSmithKline (GSK) and Shire made at the end of March 2009.
Underlying profitability (recurring EBITDA) and net profit performance were also in line with the company’s expectation.
For more information, please click the link below:
UCB
